期刊
ANNUAL REVIEW OF NEUROSCIENCE
卷 31, 期 -, 页码 175-193出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev.neuro.31.060407.125529
关键词
Alzheimer disease; vaccination; monoclonal antibody
资金
- NIA NIH HHS [R37 AG013956, R01 AG013956, AG20222, AG13956, R01 AG020222] Funding Source: Medline
- NINDS NIH HHS [K08 NS049237-02, K08 NS049237-05, K08 NS049237, K08 NS049237-04, K08 NS049237-01, K08 NS049237-03, NS049237] Funding Source: Medline
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS049237] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG013956, R37AG013956, R01AG020222] Funding Source: NIH RePORTER
Immunotherapeutic strategies to combat neurodegenerative disorders have galvanized the scientific community since the first dramatic successes in mouse models recreating aspects of Alzheimer disease (AD) were reported. However, initial human trials of active amyloid-beta (A beta) vaccination were halted early because of a serious safety issue: meningoencephalitis in 6% of subjects. Nonetheless, some encouraging preliminary data were obtained, and rapid progress has been made toward developing alternative, possibly safer active and passive immunotherapeutic approaches for several neurodegenerative conditions. Many of these are currently in human trials for AD. Despite these advances, our understanding of the essential mechanisms underlying the effects seen in preclinical models and human subjects is still incomplete. Antibody-induced phagocytosis of pathological protein deposits, direct antibody-mediated disruption of aggregates, neutralization of toxic soluble proteins, a shift in equilibrium toward efflux of specific proteins from the brain, cell-mediated immune responses, and other mechanisms may all play roles depending on the specific immunotherapeutic scenario.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据